| Code | CSB-RA011656MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to SSGJ-621, designed for research targeting interleukin-33 (IL-33). IL-33 is a member of the IL-1 family of cytokines that functions as an alarmin, released from damaged or necrotic cells to alert the immune system. It acts through the ST2 receptor to promote type 2 immune responses by activating various immune cells including mast cells, eosinophils, and innate lymphoid cells. IL-33 plays critical roles in allergic inflammation, asthma, atopic dermatitis, and fibrotic diseases, while also demonstrating protective functions in cardiovascular disease and metabolic disorders.
SSGJ-621 is a therapeutic antibody candidate that has been investigated for its ability to neutralize IL-33 activity in inflammatory and allergic conditions. This biosimilar provides researchers with a valuable tool for investigating IL-33-mediated signaling pathways, exploring its dual roles in tissue repair and pathological inflammation, and studying potential therapeutic interventions in IL-33-driven diseases. The antibody enables detailed mechanistic studies of type 2 immunity and alarmin biology across various disease models.
There are currently no reviews for this product.